Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, currently under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech’s portfolio alongside BPL-003, the company’s lead candidate for upcoming MHRA-approved Phase IIa studies in depression and Alcohol Use Disorder (AUD).

Following on from last year, Beckley Psytech will again attend the Jefferies London Healthcare Conference and will hold a formal company presentation.

All equity acquisition adds short-acting psilocin candidate for broad range of indications to Beckley Psytech's portfolio of psychedelic assets. Expanded clinical pipeline will deliver multiple value inflection points over next 18 months. Phase 1 single ascending dose study of ELE-101 to initiate before the end of 2022. Lead 5-MeO-DMT formulation BPL-003 selected for upcoming Phase 2 studies in depression.

We are happy to announce the arrival of Ruth Bateson as Senior Director, Clinical Operations and Charlotte Chorley as Communications Lead.

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey.

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress 2022.

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices. Data from Phase 1 will be used to select lead compound for upcoming Phase 2 in treatment resistant depression (TRD).

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 32nd Annual Oppenheimer Healthcare Conference